We are live on
!
Find out more
AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.94B
1-Year Est. Return
374.45%
This Fund
S&P 500
This Quarter
Est. Return
+19.79%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$358M
AUM Growth
+$121M
(+51%)
Cap. Flow
+$99.3M
Cap. Flow
% of AUM
27.73%
Top 10 Holdings %
Top 10 Hldgs %
55.61%
Holding
85
New
30
Increased
11
Reduced
11
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$13.4M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$10.5M |
| 3 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
+$6.12M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$5.02M |
| 5 |
AstraZeneca
AZN
|
+$4.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
+$7.61M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$5.98M |
| 3 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$5.69M |
| 4 |
RPTX
Repare Therapeutics
RPTX
|
+$4.49M |
| 5 |
Kura Oncology
KURA
|
+$3.89M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.05% |
| 2 | Financials | 0.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Viridian Therapeutics
VRDN
$2.1B
| – | – |
-20,660
| Closed | -$239K |
|
|
KRTX
77
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| – | – |
-45,000
| Closed | -$5.69M |
|
|
KRTX
78
PUT
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| – | – |
-45,000
| Closed | -$5.69M |
|
|
SNCE
79
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| – | – |
-13,989
| Closed | -$562K |
|
|
HZNP
80
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-75,000
| Closed | -$5.98M |
|
Similar funds
FM
1SB
HCL
OCM
MWA
AF
NFG
HC
Affinity Asset Advisors's Q3 2022 Portfolio in Review
As of Q3 2022, Affinity Asset Advisors held 85 positions worth $358M, up 51% from $237M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Affinity Asset Advisors deployed $99.3M of net new capital in Q3 2022, opening 30 new positions and adding to 11 existing holdings. Its largest new stake was Sanofi: 300,000 shares worth $11.4M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 64% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Inari Medical, Inc. Common Stock, an estimated $7.61M trimmed.
- Affinity Asset Advisors's largest Q3 2022 buy was Sanofi: 300,000 shares worth $11.4M.
- Affinity Asset Advisors added most to POINT Biopharma Global Inc. Common Stock in Q3 2022, an estimated $6.12M increase.
- Affinity Asset Advisors's biggest Q3 2022 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $7.61M.
- Affinity Asset Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $5.98M.
- Affinity Asset Advisors's ten largest holdings make up 56% of its $358M portfolio in Q3 2022.
- Affinity Asset Advisors opened 30 new positions and closed 21 in Q3 2022.
- Affinity Asset Advisors's portfolio value rose 51% quarter-over-quarter to $358M.
Based on Affinity Asset Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.